{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:42:41Z","timestamp":1774878161685,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00277-023-05113-9","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:03:24Z","timestamp":1675422204000},"page":"841-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ibrutinib in relapsed\/refractory patients with Waldenstr\u00f6m macroglobulinemia: a real-life, retrospective study on behalf of the \u201cRTL\u201d (regional Tuscan lymphoma network)"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9706","authenticated-orcid":false,"given":"Emanuele","family":"Cencini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ghio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Bertaggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Giachetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Pirrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia Lucco","family":"Navei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cervetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Sant\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Birtolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"issue":"2","key":"5113_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.18036","volume":"197","author":"G Pratt","year":"2022","unstructured":"Pratt G, El-Sharkawi D, Kothari J, D\u2019Sa S, Auer R, McCarthy H, Krishna R, Miles O, Kyriakou C, Owen R (2022) Diagnosis and management of Waldenstr\u00f6m macroglobulinaemia-a British Society for Haematology guideline. Br J Haematol 197(2):171\u2013187. https:\/\/doi.org\/10.1111\/bjh.18036","journal-title":"Br J Haematol"},{"issue":"Suppl 4","key":"5113_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/annonc\/mdy322","volume":"29","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C, Guidelines Committee ESMO (2018) Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):41\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdy322","journal-title":"Ann Oncol"},{"issue":"2","key":"5113_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ajh.26082","volume":"96","author":"MA Gertz","year":"2021","unstructured":"Gertz MA (2021) Waldenstr\u00f6m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 96(2):258\u2013269. https:\/\/doi.org\/10.1002\/ajh.26082","journal-title":"Am J Hematol"},{"issue":"9","key":"5113_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR (2012) MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 367(9):826\u2013833. https:\/\/doi.org\/10.1056\/NEJMoa1200710","journal-title":"N Engl J Med"},{"issue":"18","key":"5113_CR5","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","volume":"123","author":"SP Treon","year":"2014","unstructured":"Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123(18):2791\u20132796. https:\/\/doi.org\/10.1182\/blood-2014-01-550905","journal-title":"Blood"},{"issue":"7","key":"5113_CR6","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP (2013) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia. Blood 122(7):1222\u20131232. https:\/\/doi.org\/10.1182\/blood-2012-12-475111","journal-title":"Blood"},{"issue":"22","key":"5113_CR7","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","volume":"25","author":"MA Dimopoulos","year":"2007","unstructured":"Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G (2007) Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344\u20133349. https:\/\/doi.org\/10.1200\/JCO.2007.10.9926","journal-title":"J Clin Oncol"},{"issue":"1","key":"5113_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjh.15718","volume":"186","author":"K Laribi","year":"2019","unstructured":"Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V (2019) Bendamustine plus rituximab in newly-diagnosed Waldenstr\u00f6m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol 186(1):146\u2013149. https:\/\/doi.org\/10.1111\/bjh.15718","journal-title":"Br J Haematol"},{"issue":"2","key":"5113_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bjh.15582","volume":"184","author":"E Cencini","year":"2019","unstructured":"Cencini E, Sicuranza A, Fabbri A, Ferrigno I, Rigacci L, Cox MC, Raspadori D, Bocchia M (2019) Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-Hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. Br J Haematol 184(2):223\u2013231. https:\/\/doi.org\/10.1111\/bjh.15582","journal-title":"Br J Haematol"},{"issue":"13","key":"5113_CR10","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1200\/JCO.2009.23.6315","volume":"28","author":"D Laszlo","year":"2010","unstructured":"Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G (2010) Rituximab and subcutaneous 2-chloro-2\u2019-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 28(13):2233\u20132238. https:\/\/doi.org\/10.1200\/JCO.2009.23.6315","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"5113_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/10428194.2011.570395","volume":"52","author":"F Lauria","year":"2011","unstructured":"Lauria F, Cencini E, Forconi F (2011) Alternative methods of cladribine administration. Leuk Lymphoma 52(Suppl 2):34\u201337. https:\/\/doi.org\/10.3109\/10428194.2011.570395","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"5113_CR12","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1182\/blood-2018-07-863241","volume":"132","author":"R Sklavenitis-Pistofidis","year":"2018","unstructured":"Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM (2018) Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood 132(24):2608\u20132612. https:\/\/doi.org\/10.1182\/blood-2018-07-863241","journal-title":"Blood"},{"issue":"1","key":"5113_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O\u2019Brien S (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1215637","journal-title":"N Engl J Med"},{"issue":"4","key":"5113_CR14","first-page":"373","volume":"11","author":"E Cencini","year":"2021","unstructured":"Cencini E, Mecacci B, Morelli F, Ghio F, Romano I, Birtolo S, Simonetti F, Zoi V, Moretti S, Sant\u2019Antonio E, Cuccaro A, Santini S, Kovalchuk S, Galimberti S, Bocchia M, Fabbri A (2021) Ibrutinib in patients with relapsed\/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the \u201cRTL\u201d (regional Tuscan lymphoma network). Am J Blood Res 11(4):373\u2013383","journal-title":"Am J Blood Res"},{"issue":"22","key":"5113_CR15","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","volume":"4","author":"A Noy","year":"2020","unstructured":"Noy A, de Vos S, Coleman M, Martin P, Flowers CR, Thieblemont C, Morschhauser F, Collins GP, Ma S, Peles S, Smith SD, Barrientos JC, Chong E, Wu S, Cheung LW, Kwei K, Hauns B, Arango-Hisijara I, Chen R (2020) Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv 4(22):5773\u20135784. https:\/\/doi.org\/10.1182\/bloodadvances.2020003121","journal-title":"Blood Adv"},{"issue":"15","key":"5113_CR16","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH (2015) Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 372(15):1430\u20131440. https:\/\/doi.org\/10.1056\/NEJMoa1501548","journal-title":"N Engl J Med"},{"issue":"2","key":"5113_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, Garc\u00eda-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C, iNNOVATE Study Group and the European Consortium for Waldenstr\u00f6m\u2019sMacroglobulinemia (2017) Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 18(2):241\u2013250. https:\/\/doi.org\/10.1016\/S1470-2045(16)30632-5","journal-title":"Lancet Oncol"},{"issue":"4","key":"5113_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/hon.2503","volume":"36","author":"G Boriani","year":"2018","unstructured":"Boriani G, Corradini P, Cuneo A, Falanga A, Fo\u00e0 R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL (2018) Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol 36(4):624\u2013632. https:\/\/doi.org\/10.1002\/hon.2503","journal-title":"Hematol Oncol"},{"issue":"6","key":"5113_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ajh.24366","volume":"91","author":"JN Gustine","year":"2016","unstructured":"Gustine JN, Meid K, Dubeau TE, Treon SP, Castillo JJ (2016) Atrial fibrillation associated with ibrutinib in Waldenstr\u00f6m macroglobulinemia. Am J Hematol 91(6):312\u2013313. https:\/\/doi.org\/10.1002\/ajh.24366","journal-title":"Am J Hematol"},{"issue":"3","key":"5113_CR20","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1097\/HS9.0000000000000363","volume":"4","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP (2020) Response and survival outcomes to ibrutinib monotherapy for patients with Waldenstr\u00f6m macroglobulinemia on and off clinical trials. Hemasphere 4(3):e363. https:\/\/doi.org\/10.1097\/HS9.0000000000000363","journal-title":"Hemasphere"},{"issue":"3","key":"5113_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1182\/bloodadvances.2021006106","volume":"6","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Sarosiek SR, Gustine JN, Flynn CA, Leventoff CR, White TP, Meid K, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Hunter ZR, Patterson CJ, Branagan AR, Treon SP (2022) Response and survival predictors in a cohort of 319 patients with Waldenstr\u00f6m macroglobulinemia treated with ibrutinib monotherapy. Blood Adv 6(3):1015\u20131024. https:\/\/doi.org\/10.1182\/bloodadvances.2021006106","journal-title":"Blood Adv"},{"issue":"3","key":"5113_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.16168","volume":"188","author":"JP Abeykoon","year":"2020","unstructured":"Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P (2020) Ibrutinib monotherapy outside of clinical trial setting in Waldenstr\u00f6m macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol 188(3):394\u2013403. https:\/\/doi.org\/10.1111\/bjh.16168","journal-title":"Br J Haematol"},{"issue":"2","key":"5113_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP, VIth International Workshop on Waldenstr\u00f6mmacroglobulinaemia (2013) Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 160(2):171\u2013176. https:\/\/doi.org\/10.1111\/bjh.12102","journal-title":"Br J Haematol"},{"issue":"6","key":"5113_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1200\/JCO.20.00555","volume":"39","author":"SP Treon","year":"2021","unstructured":"Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, Patterson CJ, Hunter ZR, Branagan AR, Laubach JP, Ghobrial IM, Palomba ML, Advani R, Castillo JJ (2021) Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol 39(6):565\u2013575. https:\/\/doi.org\/10.1200\/JCO.20.00555","journal-title":"J Clin Oncol"},{"issue":"5","key":"5113_CR25","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/cancers12051328","volume":"12","author":"B George","year":"2020","unstructured":"George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, Mamgain M, Singhal NK, Sehgal L, Jain N (2020) Ibrutinib resistance mechanisms and treatment strategies for B cell lymphomas. Cancers (Basel) 12(5):1328. https:\/\/doi.org\/10.3390\/cancers12051328","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5113_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.21.00838","volume":"40","author":"C Buske","year":"2022","unstructured":"Buske C, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA (2022) Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol 40(1):52\u201362. https:\/\/doi.org\/10.1200\/JCO.21.00838","journal-title":"J Clin Oncol"},{"issue":"3","key":"5113_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/hon.2982","volume":"40","author":"S Ferrero","year":"2022","unstructured":"Ferrero S, Gentile M, Laurenti L, Mauro FR, Martelli M, Sportoletti P, Visco C, Zinzani PL, Tedeschi A, Varettoni M (2022) Use of BTK inhibitors with special focus on ibrutinib in Waldenstr\u00f6m macroglobulinemia: an expert panel opinion statement. Hematol Oncol 40(3):332\u2013340. https:\/\/doi.org\/10.1002\/hon.2982","journal-title":"Hematol Oncol"},{"issue":"3","key":"5113_CR28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bjh.17225","volume":"192","author":"JJ Castillo","year":"2021","unstructured":"Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, Advani RH, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP (2021) Partial response or better at six months is prognostic of superior progression-free survival in Waldenstr\u00f6m macroglobulinaemia patients treated with ibrutinib. Br J Haematol 192(3):542\u2013550. https:\/\/doi.org\/10.1111\/bjh.17225","journal-title":"Br J Haematol"},{"issue":"18","key":"5113_CR29","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fern\u00e1ndez de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M (2020) A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood 136(18):2038\u20132050. https:\/\/doi.org\/10.1182\/blood.2020006844","journal-title":"Blood"},{"issue":"2","key":"5113_CR30","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","volume":"7","author":"RG Owen","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S, D\u2019Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR (2020) Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 7(2):e112\u2013e121. https:\/\/doi.org\/10.1016\/S2352-3026(19)30210-8","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05113-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05113-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05113-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T21:13:17Z","timestamp":1678396397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05113-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5113"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05113-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University of Siena approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}